Daiichi makes play for share of Japan’s COVID booster market

Daiichi makes play for share of Japan’s COVID booster market

Source: 
Pharmaforum
snippet: 

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 that focuses on its use as a booster dose.